[8-K] ClearPoint Neuro, Inc. Reports Material Event

Rhea-AI Filing Summary

ClearPoint Neuro (CLPT) furnished an 8-K announcing it issued a press release with financial results for the third fiscal quarter ended September 30, 2025, and posted an updated investor presentation.

The press release is provided as Exhibit 99.1 and the investor presentation as Exhibit 99.2. The company noted these materials are being furnished, not filed, and are not incorporated by reference except as expressly set forth in future filings.

false000128555000012855502025-11-062025-11-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 06, 2025

CLEARPOINT NEURO, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-34822	58-2394628
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
120 S. Sierra Ave., Suite 100
Solana Beach, California				92075
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 888 287-9109

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value per share		CLPT		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2025, ClearPoint Neuro, Inc. (the “Company”) issued a press release announcing its financial results for the third fiscal quarter ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.

The information in Item 2.02 of this Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 7.01 Regulation FD Disclosure.

On November 6, 2025, the Company posted an updated investor presentation to its website at http://ir.stockpr.com/clearpointneuro/investor-presentations. A copy of the investor presentation is being furnished herewith as Exhibit 99.2. The Company may use the investor presentation from time to time in conversations with analysts, investors and others.

The information in Item 7.01 of this Form 8-K, as well as Exhibit 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished herewith:

Exhibit 99.1	Press Release dated November 6, 2025
Exhibit 99.2	Investor Presentation dated November 6, 2025
Exhibit 104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			CLEARPOINT NEURO, INC.
Date:	November 6, 2025	By:	/s/ Danilo D'Alessandro
			Danilo D'Alessandro Chief Financial Officer

FAQ

What did ClearPoint Neuro (CLPT) announce?

The company furnished an 8-K stating it issued a press release with Q3 2025 results and posted an updated investor presentation.

Which period do the results cover for CLPT?

The results cover the third fiscal quarter ended September 30, 2025.

What exhibits were included in CLPT’s 8-K?

Exhibit 99.1 is the press release dated November 6, 2025, and Exhibit 99.2 is the investor presentation dated November 6, 2025.

Are the exhibits considered filed or furnished?

They are furnished, not filed, and are not incorporated by reference except as expressly set forth in a future filing.

Where can investors access the presentation?

The investor presentation was posted to the company’s website at http://ir.stockpr.com/clearpointneuro/investor-presentations.

What is CLPT’s trading market and symbol?

Common stock trades on The Nasdaq Stock Market under the symbol CLPT.